



PATENT
Attorney Docket No. 056291-5256

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Margaretha Grind)	
)	
Application No. 10/550,154)	Art Unit: 1654
)	
Filed: September 20, 2005)	Examiner: Hemant Khanna
)	
For: USE OF LOW MOLECULAR WEIGHT)	
THROMBIN INHIBITORS IN)	
CHOLESTEROL-LOWERING THERAPY)	

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, **Mail Stop Amendment**
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Date: January 4, 2007

Sir

AMENDMENT UNDER 37 C.F.R. § 1.111

This paper responds to the Office Action, dated September 6, 2006, time for response to which expired December 6, 2006. A one month extension of time is filed concurrently, thereby extending the period for response to January 6, 2007.

Applicants respectfully request reconsideration of this application in view of the following amendments and remarks.

Please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims begin on page 3 of this paper.

Remarks/Arguments begin on page 13 of this paper.

Amendments to the Specification:

Please replace the paragraph on page 18, at lines 23-26 with the following:

Brief Description of the Drawings

Figure 1 illustrates the difference in mean values (with 95% Confidence Intervals) of total cholesterol levels in serum as between patients receiving ximelagatran (36 mg bid) or warfarin (INR levels between 2 and 3) during the course of a clinical trial over a 21 month period.